Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1611 1615 1617 1626 1792
This examiner grants 57% of resolved cases
Peter Anthopolos serves in Tech Center 1600 within Art Unit 1600. The examiner has 531 resolved cases with an allowance rate of 57.3 percent. This indicates that more than half of the applications are allowed. The median days to allowance is 1230, which serves as a benchmark for the expected duration of the prosecution process.
The most notable metric is the interview lift of 59.0 percent. This high lift suggests that interviews are exceptionally effective at improving the chances of allowance compared to the 57.3 percent baseline. Practitioners should prioritize scheduling an interview to address examiner concerns directly. With 531 resolved cases, the statistical evidence for the benefits of an interview is very strong. Utilizing the interview process may be the most effective way to navigate the 1230-day median pendency and secure an allowance in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | Non-Final OA | Novo Nordisk A/S |
| 16170516 | COMPOSITIONS HAVING ENHANCED DEPOSITION OF SURFACTANT SOLUBLE ANTIDANDRUFF AGENTS | Final Rejection | The Procter & Gamble Company |
| 18695845 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | Non-Final OA | The Regents of the University of Michigan |
| 18729607 | UV FILTER COMPOSITIONS COMPRISING CLOSED-CELL METAL OXIDE PARTICLES | Non-Final OA | BASF SE |
| 19303799 | PHARMACEUTICAL COMPOSITIONS | Final Rejection | CALLIDITAS THERAPEUTICS AB |
| 19242077 | PHARMACEUTICAL COMPOSITIONS | Non-Final OA | CALLIDITAS THERAPEUTICS AB |
| 19195082 | PHARMACEUTICAL COMPOSITIONS | Non-Final OA | CALLIDITAS THERAPEUTICS AB |
| 19194972 | PHARMACEUTICAL COMPOSITIONS | Final Rejection | CALLIDITAS THERAPEUTICS AB |
| 18352811 | PHARMACEUTICAL COMPOSITIONS | Non-Final OA | CALLIDITAS THERAPEUTICS AB |
| 18417024 | INJECTABLE PROLONGED-RELEASE HYDROGEL FORMULATIONS OF TOLL-LIKE RECEPTOR AGONISTS FOR INTRATUMORAL INJECTION TO INCREASE IMMUNOTHERAPY RESPONSE | Final Rejection | The General Hospital Corporation |
| 18954915 | Anhydrous Sunscreen Compositions With enhanced Ultraviolet Protection | Non-Final OA | ELC Management LLC |
| 18799051 | Elastic Biopolymer and Use as a Tissue Adhesive | Non-Final OA | The Brigham and Women's Hospital, Inc |
| 17441162 | EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF | Non-Final OA | LONZA SALES AG |
| 17842110 | COMPOSITIONS AND METHODS FOR AERODIGESTIVE TREATMENT | Final Rejection | WIAB WATER INNOVATION AB |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18562059 | HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy